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H1N1 Influenza Virus 
By: Kail Consford and Drew Patel 
 
Background 
 
Background 
On April 17, 2009,  two patients in the United States were found with 
Swine-Origin Influenza A (H1N1) virus.  This virus was spread to 
Mexico, Canada, and many other countries.  From April 15 through 
May 5, a total of 642 confirmed cases of H1N1 infection were identified 
in 41 states.  The ages of the patients were from 3 months to 81 years, 
and 60% of the patients were 18 or younger.   Most of these patients 
recently came from either Mexico or even from school outbreaks.  The 
most common symptoms were fever, cough, and a sore throat.  The 
H1N1 was determined to have a unique genome composition that had 
not been identified previously (Padilla et al., 2009). 
 
Historical 
“Studies performed over the past 15 years have confirmed the 
therapeutic benefit of amantadine when given early in the course of 
acute illness due to influenza A virus, both in shortening their 
symptoms and decreasing their severity.  Despite the reports, 
amantadine is not used in medicine very often.  Clinicians were 
concerned about the side effects of amantadine and may be convinced 
that other drugs, such as aspirin, are just as effective in relieving 
symptoms and controlling fever.  During an outbreak of influenza 
A/Brazil/78 H1N1 infection in the winter of 1981, a controlled double-
blind study was performed comparing the therapeutic advantages and 
disadvantages of amantadine and aspirin for the treatment of 
influenza.  Low and high doses of amantadine were compared to 
determine if side effects could be preventable (Younkinh, Betts, Roth, 
& Douglas, 1983). 
 
Microorganism 
H1N1 is an influenza virus that is related to the swine flu.  Influenza 
viruses cause epidemics of respiratory illness and pandemics.  Like all 
viruses, influenza relies on the host cellular machinery to support their 
life cycle.  Efforts to control these outbreaks and real-time monitoring 
of the evolution of this virus should provide us with invaluable 
information to direct infectious disease control programmers and to 
improve understanding of the factors that determine viral 
pathogenicity and/or transmissibility (Plennevaux et al., 2009). 
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Infection/Disease 
 
Immune response 
H1N1 goes through immune response with the three lines of defense.  
The first line of defense had goes through a sore throat, runny nose, 
and coughing stage.  It soon became air born.  The second non-specific 
line of defense began with a 99.0 F.  The third specific line of defense 
was developing severe pneumonia.  The patients with pneumonia had 
no distinguishing epidemiologic, clinical, or laboratory features 
(Plennevaux et al., 2009). 
 
 
 Progression 
Doctors used amantadine 
to control fevers and relieve 
symptoms.  Patients without 
amantadine increased their  
risk in death.  Doctors try  
to decide whether more doses 
of amantadine will prevent the 
side effects.  They also study the 
symptoms to see what else they                      How the H1N1 cell is                                
need to prevent to find a vaccine     constructed 
for H1N1 (Padilla et al., 2009). 
 
        Prognosis 
Mexico had reported 4,910 confirmed cases and 85 deaths caused by 
H1N1.  Mexico had the most severe H1N1 cases than any other country 
and also had the most patients with the virus.  Pneumonia was the 
worst side effect and the hardest to get rid of.  Doctors reviewed 
clinical data from patients with influenza-like illnesses and pneumonia 
with a negative result on H1N1.  They took swabs to study the effects of 
medicines so that they could which medicines helped with the 
symptoms of H1N1.  Once primers and probes were developed, they 
sent the vaccines to Mexico to hopefully reduce the cases of h1n1 and 
deaths (Ginocchio et al., 2009). 
 
 
 
 
 
                                                                                     
 
 
 
Treatment 
Options 
H1N1 can cause illness, respiratory distress syndrome, and death. 
Because of these symptoms, this virus is very deadly to all ages. 
Doctors came to the conclusion that amantadine would be a necessary 
treatment for this virus.  Amantadine helps control high fever and 
relieves the symptoms of H1N1.  Doctors also tried the adding of oil-
and-water to a TIV but did not increase the frequency of response in 
2009.   Microneutralization assay was another technique used by the 
Centers for Disease Control and Prevention to prove some adults have 
serum cross-reactive antibodies to the H1N1 virus.  Because of the 
results of only one out of 124 children with this antibody at the level of 
40, they had an increase to the 2009 H1N1 strain after receipt of 
“seasonal trivalent inactivated influenza vaccine” (World Health 
Organization, 2010).  
 
Mechanism 
Patients began getting doses of medications receiving it at admission (A 
mean of 8 days after the onset of symptoms). Each patient was given an 
antibiotic to help doctors find witch antibiotic showed the most 
improvement. Doctors tried different vaccines for patients that had 
different symptoms to see if their symptoms would lesson. After trying 
corticosteroids, five out of six patients died. They tried many more 
vaccines after they found what was in the corticosteroids that made the 
five patients die (Nishiura, 2009). 
 
Emerging 
Although antigen based tests require little technical skill, are rapid and 
can be performed in an emergency department setting, the sensitivity 
and specificity of the assays are questionable.  BinaxNOW assay (a 
swine-flu test) demonstrated very poor sensitivity for the detection of 
both seasonal influenza A compared to R-Mix culture.  (Padilla et al., 
2009).  
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